Investment in securities market are subject to market risks. Read all the related documents carefully before investing
Industry Veteran with Two Decades of Experience Reveals
Our Big Prediction
**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
LAURUS LABS Share Price (LAUL)
Here is the latest stock price and chart of LAURUS LABS . For more details, see the LAURUS LABS company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
| Live BSE Quotes | Sep 15, 2026 (Close) | ||
|---|---|---|---|
| Price (Rs)1,923.00 | Open (Rs) 1,973.00 | High (Rs) 1,981.00 | Low (Rs) 1,914.95 |
| % Change-2.40 | Volume 76,272 | Value (Rs) 147,773,973 | 52-Week H/L 1,981.45 / 822.85 |
| Live NSE Quotes | Sep 15, 2026 (Close) | ||
|---|---|---|---|
| Price (Rs)1,926.90 | Open (Rs) 1,975.00 | High (Rs) 1,981.00 | Low (Rs) 1,915.60 |
| % Change-2.14 | Volume 1,538,262 | Value (Rs) 2,980,735,744 | 52-Week H/L 1,981.80 / 823.10 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -2.40% | 1 Month 6.89% | 3 Months 38.42% | 1 Year 115.10% | 5 Years (CAGR)* 23.75% | 10 Years (CAGR)* 34.94% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 20.19 | P/E Ratio (x) 95.26 | Market Cap (Rs m) 1,039,020.36 | P/BV (x) 18.88 | Dividend Yield (%) 0.10 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
LAURUS LABS Share Price Today:
LAURUS LABS last traded price was down 2.4% to Rs 1,923.0 on the BSE. On the NSE, LAURUS LABS last traded price was down 2.1% to Rs 1,926.9. The total volume of shares traded was 1.6 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.5%. And the benchmark S&P BSE SENSEX was at 74,003.8 (down 1.0%).
Over the last 30 days, the LAURUS LABS share price is up 3.4%. And over the last one year, LAURUS LABS share price is up 114.9%.
The current market capitalisation of LAURUS LABS stands at Rs 1,039,020.36 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of June 2026, promoter pledging in LAURUS LABS stands at 2.69%. To know more, check out the latest shareholding pattern of LAURUS LABS .
FAQs on LAURUS LABS
What is the LAURUS LABS share price today?
The last traded price of LAURUS LABS was Rs 1,923.0 on the BSE, down 2.4% over the previous close. On the NSE, LAURUS LABS last traded price was down 2.1% at Rs 1,926.9.
What is the market cap of LAURUS LABS ?
The current market capitalisation of LAURUS LABS stands at Rs 1,039,020 m. For more information, check out the list of top 100 companies in India in terms of market cap.
What is the Earnings per share (EPS) of LAURUS LABS ?
LAURUS LABS had an EPS of Rs 20.2 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 6.7.
What is the PE Ratio and PB Ratio of LAURUS LABS ?
What is the Dividend Yield of LAURUS LABS ?
For the financial year 2026, LAURUS LABS declared dividend amounting to Rs 2.0 per share. At the current price of Rs 1,923.0, this results in a dividend yield of 0.1%.
Which are the top pharmaceuticals companies in India by marketcap?
Based on marketcap, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks ranked by marketcap here.
Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.
Which are the biggest pharmaceuticals companies in India by sales?
Based on sales, these are the top pharmaceuticals companies in India:
- #1 SUN PHARMA
- #2 DR. REDDYS LAB
- #3 AUROBINDO PHARMA
- #4 CIPLA
- #5 LUPIN
You can see the full list of pharmaceuticals stocks.
Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.
Which are the biggest pharmaceuticals companies in India by net profit?
Based on net profit, these are the top pharmaceuticals companies in India:
- #1 SUN PHARMA
- #2 LUPIN
- #3 ZYDUS LIFESCIENCES
- #4 DR. REDDYS LAB
- #5 CIPLA
You can see the full list of pharmaceuticals stocks.
In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.
Today's Market
![]()
Sensex Today Plunges 777 Points | Nifty Below 23,200 | 3 Reasons Why Indian Stock Markets Are Falling(Closing)
Sensex Today Plunges 777 Points | Nifty Below 23,200 | 3 Reasons Why Indian Stock Markets Are FallingBenchmark indices Sensex and Nifty significantly fell from day's high to end in deep red on September 15 due to various reasons, including higher oil prices and global bond yields.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
- Hidden Treasure
- Forever Stocks
- Big Wave Profits
- Equitymaster Venture
- Microcap Millionaires
- Momentum Profits
- Double Income
- Midcap Value Alert
- Exponential Profits
- Annual Breakout Alert
- Lazy Millionaire
- Phase One Alert
- InsiderPro Stocks
- StockSelect
- Private Briefing
- Active Wealth Multiplier 2030
- FundSelect
- Fund Advantage
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
- Best Defence Stocks in India
- Upcoming Dividend Stocks
- Best Semiconductor Stocks in India
- Data Center Stocks in India
- Best Railway Stocks in India
- Best Solar Stocks in India
- Fastest Growing Stocks in India
- List of BSE Sensex 30 Stocks
- Adani Group Shares
- Stocks Recently Bought by FIIs in India
- Top Value Stocks in India
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.
Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.
The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.